These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 11190204)

  • 21. International veterinary bioequivalence guideline similarities and differences between Australia, Canada, Europe, Japan, New Zealand and the United States.
    Lainesse C
    AAPS J; 2012 Dec; 14(4):792-8. PubMed ID: 22864669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New bioequivalence studies: individual bioequivalence and population bioequivalence.
    Nakai K; Fujita M; Ogata H
    Yakugaku Zasshi; 2000 Nov; 120(11):1201-8. PubMed ID: 11190205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Bioequivalence and generics of index drugs with narrow therapeutic margins].
    Le Corre P
    Presse Med; 2010 Feb; 39(2):169-76. PubMed ID: 19932591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Generic drugs: quality, efficacy, safety and interchangeability].
    Tschabitscher D; Platzer P; Baumgärtel C; Müllner M
    Wien Klin Wochenschr; 2008; 120(3-4):63-9. PubMed ID: 18322766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What makes a generic medication generic?
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2009 Dec; 47(12):17-20. PubMed ID: 20000278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bioequivalence Evaluations of Generic Dry Powder Inhaler Drug Products: Similarities and Differences Between Japan, USA, and the European Union.
    Kuribayashi R; Yamaguchi T; Sako H; Takishita T; Takagi K
    Clin Pharmacokinet; 2017 Mar; 56(3):225-233. PubMed ID: 27461251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Harmonization of regulatory approaches for evaluating therapeutic equivalence and interchangeability of multisource drug products: workshop summary report.
    Chen ML; Shah VP; Crommelin DJ; Shargel L; Bashaw D; Bhatti M; Blume H; Dressman J; Ducharme M; Fackler P; Hyslop T; Lutter L; Morais J; Ormsby E; Thomas S; Tsang YC; Velagapudi R; Yu LX
    Eur J Pharm Sci; 2011 Nov; 44(4):506-13. PubMed ID: 21946259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug substitution in transplantation: a National Kidney Foundation White Paper.
    Sabatini S; Ferguson RM; Helderman JH; Hull AR; Kirkpatrick BS; Barr WH
    Am J Kidney Dis; 1999 Feb; 33(2):389-97. PubMed ID: 10023656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Classification of torasemide based on the Biopharmaceutics Classification System and evaluation of the FDA biowaiver provision for generic products of CLASS I drugs.
    Khan MZ; Rausl D; Radosević S; Filić D; Danilovski A; Dumić M; Knezević Z
    J Pharm Pharmacol; 2006 Nov; 58(11):1475-82. PubMed ID: 17132210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bioequivalence and switchability of generic antiseizure medications (ASMs): A re-appraisal based on analysis of generic ASM products approved in Europe.
    Odi R; Franco V; Perucca E; Bialer M
    Epilepsia; 2021 Feb; 62(2):285-302. PubMed ID: 33426641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current regulatory approaches of bioequivalence testing.
    Karalis V; Macheras P
    Expert Opin Drug Metab Toxicol; 2012 Aug; 8(8):929-42. PubMed ID: 22681436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dissolution and in vivo evidence of differences in reference products: impact on development of generic drugs.
    Spino M; Tsang YC; Pop R
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):18-24. PubMed ID: 11032084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability.
    Bialer M; Midha KK
    Epilepsia; 2010 Jun; 51(6):941-50. PubMed ID: 20384761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of Different Populations on Pharmacokinetic Bioequivalence Results: Can We Extrapolate Bioequivalence Results from One Population to Another?
    Ozdin D; Ducharme MP; Varin F; Fuglsang A; Al-Numani D
    J Pharm Pharm Sci; 2020; 23():. PubMed ID: 33064978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro and In silico biopharmaceutic regulatory guidelines for generic bioequivalence for oral products: Comparison among various regulatory agencies.
    Kollipara S; Ahmed T; Bhattiprolu AK; Chachad S
    Biopharm Drug Dispos; 2021 Jul; 42(7):297-318. PubMed ID: 34019712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigation on the need of multiple dose bioequivalence studies for prolonged-release generic products.
    García-Arieta A; Morales-Alcelay S; Herranz M; de la Torre-Alvarado JM; Blázquez-Pérez A; Suárez-Gea ML; Alvarez C
    Int J Pharm; 2012 Feb; 423(2):321-5. PubMed ID: 22120644
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical, Pharmacokinetic, and In Vitro Studies to Support Bioequivalence of Ophthalmic Drug Products.
    Choi SH; Lionberger RA
    AAPS J; 2016 Jul; 18(4):1032-8. PubMed ID: 27184578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjusted indirect comparisons to assess bioequivalence between generic clopidogrel products in Serbia.
    Pejčić Z; Vučićević K; García-Arieta A; Miljković B
    Br J Clin Pharmacol; 2019 Sep; 85(9):2059-2065. PubMed ID: 31140620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current methodology to assess bioequivalence of levothyroxine sodium products is inadequate.
    Blakesley VA
    AAPS J; 2005 Mar; 7(1):E42-6. PubMed ID: 16146348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioavailability and Bioequivalence Aspects of Oral Modified-Release Drug Products.
    Wang R; Conner DP; Li BV
    AAPS J; 2017 Mar; 19(2):360-366. PubMed ID: 28004346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.